Novo Nordisk (NYSE:NVO) said today that the European Union’s Committee for Medicinal Products for Human Use issued a positive opinion on its fast-acting insulin analogue, Fiasp. The Danish company also committed to expanding its Changing Diabetes in Children program, which provides access to diabetes care and free insulin to children with Type I diabetes in developing countries.
The committee, under the European Medicines Agency, recommended marketing authorization for adults withType I and Type II diabetes. Fiasp is a fast-acting mealtime insulin that has a greater glucose-lowering effect than Nordisk’s NovoRapid insulin. The committee recommended that the European Commission indicate Fiasp for use as the bolus component of basal-bolus therapy in combination with basal insulin and for insulin infusion using an insulin pump.
Get the full story at our sister site, Drug Delivery Business News.
The post Novo Nordisk’s Fiasp wins EU nod; Danish firm plans emerging markets push appeared first on MassDevice.
from MassDevice http://ift.tt/2fNi3qS
Cap comentari:
Publica un comentari a l'entrada